Suppr超能文献

282 例晚期或复发性宫颈癌盆腔廓清术患者的适应证及长期临床结局。

Indications and long-term clinical outcomes in 282 patients with pelvic exenteration for advanced or recurrent cervical cancer.

机构信息

Department of Gynecology, University Hospital Zurich, Zurich, Switzerland.

出版信息

Gynecol Oncol. 2012 Jun;125(3):604-9. doi: 10.1016/j.ygyno.2012.03.001. Epub 2012 Mar 7.

Abstract

OBJECTIVE

The aim of this study was to summarize the clinical experience at our clinic with pelvic exenteration as a treatment for cervical cancer with special regard to the indications and outcomes of specific patient groups.

METHODS

Medical records of 282 women who underwent pelvic exenteration to treat cervical cancer were analyzed.

RESULTS

In total, 70 patients (25%) underwent primary exenteration, and 212 (75%) underwent secondary exenteration. Exenteration was anterior for 14 (5%) patients, posterior for 6 (2%) and total for 262 (93%). The overall survival (OS) of the 282 patients was 41% at 5 years and 37% at 10 years. The disease-free survival at 5 years was 61%. For 133 patients for whom pelvic exenteration was a curative procedure, the OS was 64% at 5 years and 57% at 10 years. For cases of pelvic exenteration as a palliative intervention, the OS was 19% at 5 years and 18% at 10 years. No difference was seen in the OS at 5 years between patients who received primary and secondary operations. No significant difference in the OS was found regardless of whether the patients had positive pelvic lymph nodes, whereas in cases of paraaortic lymph node metastasis, the OS was significantly lower. Out of all of the procedures, 139 (49%) involved no perioperative or postoperative complications. One major complication was reported for 72 (26%) patients, two complications occurred for 42 patients (15%) and more than three complications were noted for 29 (10%) patients.

CONCLUSION

Pelvic exenteration is an effective technique with a high percentage of long-term survivors. To the best of our knowledge, our study involves the largest published number of patients treated with pelvic exenteration for a single gynecological cancer and shows that previous contraindications for pelvic exenteration, such as lymph node metastasis (especially when confined to the pelvic lymph nodes), older age or palliative intent, should be reconsidered.

摘要

目的

本研究旨在总结本诊所行盆腔廓清术治疗宫颈癌的临床经验,特别关注特定患者人群的适应证和结局。

方法

分析了 282 例行盆腔廓清术治疗宫颈癌的女性患者的病历。

结果

共有 70 例(25%)患者行初次廓清术,212 例(75%)行二次廓清术。14 例(5%)行前路廓清术,6 例(2%)行后路廓清术,262 例(93%)行全盆腔廓清术。282 例患者的总体生存率(OS)为 5 年时 41%,10 年时 37%。5 年时无疾病生存率为 61%。对于 133 例接受盆腔廓清术根治性治疗的患者,5 年 OS 为 64%,10 年 OS 为 57%。对于接受盆腔廓清术姑息性治疗的病例,5 年 OS 为 19%,10 年 OS 为 18%。初次手术和二次手术患者的 5 年 OS 无显著差异。无论患者是否存在盆腔淋巴结阳性,其 OS 均无显著差异,而当存在腹主动脉旁淋巴结转移时,OS 显著降低。所有手术中,139 例(49%)无围手术期或术后并发症。72 例(26%)患者报告有 1 种主要并发症,42 例(15%)患者发生 2 种并发症,29 例(10%)患者发生 3 种以上并发症。

结论

盆腔廓清术是一种有效且长期生存率高的技术。据我们所知,本研究涉及接受盆腔廓清术治疗单一妇科癌症的患者数量最多,表明先前被认为是盆腔廓清术禁忌证的因素,如淋巴结转移(特别是局限于盆腔淋巴结)、年龄较大或姑息性治疗,应重新考虑。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验